<DOC>
	<DOCNO>NCT02669615</DOCNO>
	<brief_summary>This study single-center , open-label study high-dose Melphalan HCl injection ( propylene glycol free Melphalan ) conduct 24 patient , symptomatic multiple myeloma qualify ASCT . There three distinct evaluation period trial : pretreatment period , study period follow-up period .</brief_summary>
	<brief_title>Pharmacokinetic Study Propylene Glycol-Free Melphalan HCl Myeloablative Conditioning Multiple Myeloma Patients Undergoing Autologous Transplantation</brief_title>
	<detailed_description>OVERVIEW : This study single-center , open-label study high-dose Melphalan HCl injection ( propylene glycol free Melphalan ) conduct 24 patient , symptomatic multiple myeloma qualify ASCT . There three distinct evaluation period trial : pretreatment period , study period follow-up period . PRETREATMENT : Pretreatment Period Evaluations ( Days -30 -3 ) . Baseline assessment collect within 30 day dose Melphalan HCl injection ( propylene glycol free ) , patient sign informed consent . These include clinical laboratory assessment ( e.g. , medical history physical examination , hematology , urine analysis , creatinine clearance ) , chest X-ray vital sign . STUDY TREATMENT : 1 . During study period , patient receive 200 mg/m2 Melphalan HCl injection ( propylene glycol free ) one-time infusion day 2 . Following one day rest myeloablative Melphalan conditioning ( day -1 ) , patient receive autologous graft minimum cell dose 2 × 106 CD34+ cells/kg patient body weight ( day 0 ) . 3 . Pharmacokinetic , efficacy safety evaluation perform study period . FOLLOW-UP : ASCT Day +1 Day+100 . During follow-up period , patient return daily laboratory test ( hematology basic serum chemistry ) evaluate weekly physician engraftment date , final end-of-study evaluation occur seven day engraftment date . During follow-up period , test ( e.g. , physical examination , CBC , vital sign , full serum chemistry panel , bone marrow biopsy ) perform weekly engraftment ( unless otherwise specify ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients symptomatic MM require treatment follow diagnosis . Patients MM , qualify ASCT therapy , receive pretransplant therapy prior transplantation . Adult patient ( ≥18 year age ) meeting local institutional criterion receive total Melphalan dose 200 mg/m2 condition regimen . Patients adequate autologous graft , define unmanipulated , cryopreserved , peripheral blood cell graft contain least 2 × 106 CD34+ cells/kg , base patient weight . Patients adequate organ function , measure : Cardiac : Left ventricular ejection fraction rest &gt; 40 % ( document within 30 day prior Day 3 ) . Hepatic : Bilirubin &lt; 2 × ULN ALT/AST &lt; 3 × ULN . Renal : Creatinine clearance &gt; 40 mL/min ( measure calculated/estimated ) . Pulmonary : Adjusted DLCO , FEV1 , FVC &gt; 50 % predict value ( correct Hgb ) document within prior day 3 . Patients systemic AL amyloidosis . ECOG performance status ≥2 . Patients uncontrolled hypertension . Patients serious active bacterial , viral fungal infection . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow unless approve medical monitor . Female patient pregnant ( positive ßHCG ) breastfeeding . Female patient childbearing potential , unwilling use adequate contraceptive technique one month follow study treatment Melphalan HCl injection ( propylene glycol free ) . Patients seropositive HIV . Patients unwilling provide informed consent . Patients receive concurrent anticancer therapy ( include chemotherapy , radiation , hormonal treatment , immunotherapy , exclude corticosteroid ) within 30 day prior ASCT plan receive treatment prior study discharge . Patients concurrently participate clinical study . Patients hypersensitive intolerant component study drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>Melphalan HCl</keyword>
	<keyword>Autologous Transplantation</keyword>
</DOC>